Evidence map›Paper›PMID 29387221›Full record

ArticleOncology letters2018

Association between

Huirong Ding, Xiaojing Cheng, Ning Ding, Zhihua Tian, Jun Zhu, Chunlian Zhou, Jing Shen, Yuqin Song

Open access · diamondAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Oncology letters, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed, 1 pooled it
0.4field-weighted citation impact, top 36% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 1 synthesis or guideline pooled it, 3 citations in OpenAlex.

  1. Pooled it
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 3 institutions in 1 country.

Huirong DingCentral Laboratory, Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education/Beijing), Peking University Cancer Hospital and Institute, Beijing 100142, P.R. China.
Xiaojing ChengDivision of Gastrointestinal Cancer Translational Research Laboratory, Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education/Beijing), Peking University Cancer Hospital and Institute, Beijing 100142, P.R. China.
Ning DingDepartment of Lymphoma, Peking University Cancer Hospital and Institute, Beijing 100142, P.R. China.
Zhihua TianCentral Laboratory, Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education/Beijing), Peking University Cancer Hospital and Institute, Beijing 100142, P.R. China.
Jun ZhuDepartment of Lymphoma, Peking University Cancer Hospital and Institute, Beijing 100142, P.R. China.
Chunlian ZhouDepartment of Nosocomial Infection Prevention and Control, Beijing Friendship Hospital, Capital Medical University, Beijing 100142, P.R. China.
Jing ShenCentral Laboratory, Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education/Beijing), Peking University Cancer Hospital and Institute, Beijing 100142, P.R. China.
Yuqin SongDepartment of Lymphoma, Peking University Cancer Hospital and Institute, Beijing 100142, P.R. China.
Peking University · CNCapital Medical University · CNPeking University Cancer Hospital · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Lysosomal protein transmembrane 4β (

Indexed as

diffuse large B-cell lymphomalysosomal protein transmembrane 4βpolymorphismprognosissusceptibility

Identifiers

PMID29387221
PMCPMC5768069
OpenAlexW2765717387

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.